• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Gabapentin for Alcohol Use Disorder, Redux

Gabapentin for Alcohol Use Disorder, Redux

June 10, 2020
Rehan Aziz, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Rehan Aziz, MD. Dr Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Anton RF et al, JAMA Intern Med 2020;180(5):1–9

Gabapentin has had mixed results in the treatment of alcohol use disorder (AUD), but it is clearly effective in the treatment of alcohol withdrawal syndrome (AWS). In this study, researchers tested whether gabapentin might be effective specifically in treating adults with AUD who also had a history of AWS.

The investigators conducted a 16-week randomized controlled trial comparing gabapentin to placebo. Ninety patients with AUD and a history of AWS were enrolled (44 in the gabapentin arm, 46 in the placebo arm). Here, AWS was defined as a self-reported history of withdrawal symptoms; however, those with a history of withdrawal seizures were excluded.

Participants were aged 18–70 (94% were white, 77% were men) and drank a mean of 86% of pre-treatment days, with 83% being heavy drinking days (defined as 5 or more drinks per day for men and 4 or more drinks per day for women). They were required to have been abstinent for 3 days prior to randomization. The study took place in an academic medical center and was sponsored by the National Institute on Alcohol Abuse and Alcoholism.

Gabapentin was started at 300 mg at bedtime and titrated over 5 days to 300 mg in the morning, 300 mg at noon, and 600 mg at bedtime. Patients in both groups received nine 20-minute medical management visits.

After 16 weeks, more gabapentin-treated individuals had no heavy drinking days compared with placebo (27% vs 9%, p = 0.02), with a number needed to treat (NNT) of 5.4. More ­gabapentin-treated patients also achieved total abstinence compared to placebo (18% vs 4%, p = 0.04), with an NNT of 6.2. The effect was more pronounced for patients with histories of more severe withdrawal. Among those who had reported less severe withdrawal, there was no difference between gabapentin and placebo. There was more dizziness reported in the gabapentin arm (57%) than in the placebo arm (33%; p = 0.02), but no serious adverse events were reported.

CATR’s Take
Gabapentin reduced heavy drinking days and promoted abstinence in patients with AUD who had withdrawal symptoms. However, the trial doesn’t address the effect of gabapentin beyond 4 months of use, and concerns remain regarding gabapentin misuse, addiction, and interaction with other sedating substances.
Addiction Treatment
KEYWORDS alcohol alcohol-use alcohol-use-disorder gabapentin pharmacology research research-update
Rehan Aziz, MD.

Mood Stabilizers for Bipolar Disorder in Older Adults: Special Considerations

More from this author
www.thecarlatreport.com
Issue Date: June 10, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Emerging Risks for Old Medications, CATR, May/June 2020
Gabapentin for Alcohol Use Disorder, Redux
Does Baclofen Titrated to High Doses Reduce Alcohol Use?
Amphetamines and Topiramate for Cocaine Use Disorder
E-Cigarettes vs Nicotine Replacement for Smoking Cessation
Benzodiazepines: Old Medicines, New Concerns
Muscle Relaxants: Sedatives Often Under the Radar
SAMHSA Relaxes Regulations on Methadone and Buprenorphine During COVID-19 Emergency
Gabapentin Misuse and Diversion
The “Z-Drugs”: Safety Issues and Misuse Potential
Note From the Editor-in-Chief
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.